Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 13/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555598 | 0.87 | NTRK1 (0.35) | CYP3A4NTRK1ABL1BCR | |
| SCHEMBL556510 | 0.83 | NTRK1 (0.35) | AKT1NTRK1 | |
| SCHEMBL556907 | 0.82 | REN (0.48) | RENKCNH2CYP3A4AKT1 | |
| SCHEMBL556906 | 0.82 | REN (0.48) | RENKCNH2CYP3A4AKT1 | |
| SCHEMBL557232 | 0.80 | REN (0.63) | RENKCNH2CYP3A4AKT1NTRK1 | |
| SCHEMBL556090 | 0.80 | REN (0.42) | RENKCNH2CYP3A4AKT1KDM4E | |
| SCHEMBL535120 | 0.70 | TACR3 (0.40) | — | |
| SCHEMBL556954 | 0.69 | REN (0.68) | RENKCNH2CYP3A4NTRK1 | |
| SCHEMBL555872 | 0.69 | REN (0.68) | RENKCNH2CYP3A4NTRK1 | |
| SCHEMBL557595 | 0.67 | PDE4B (0.43) | CYP3A4NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885KCNH2 1198/4885CYP3A4 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.